M&A Deal Summary

Genzyme Acquires SangStat Medical

On September 10, 2003, Genzyme acquired life science company SangStat Medical for 600M USD

Acquisition Highlights
  • This is Genzyme’s 4th transaction in the Life Science sector.
  • This is Genzyme’s 4th largest (disclosed) transaction.
  • This is Genzyme’s 6th transaction in the United States.
  • This is Genzyme’s 1st transaction in California.

M&A Deal Summary
Date 2003-09-10
Target SangStat Medical
Sector Life Science
Buyer(s) Genzyme
Deal Type Add-on Acquisition
Deal Value 600M USD
Advisor(s) BofA Securities (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

SangStat Medical

Fremont, California, United States
SangStat Medical Corp. is a biotechnology company focused on immunology and working to discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and immunosuppression areas.

Search 193,448 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genzyme

Cambridge, Massachusetts, United States

website

Category Company
Founded 1981
Sector Life Science
DESCRIPTION
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 6 of 12
Sector (Life Science) 4 of 9
Type (Add-on Acquisition) 5 of 10
State (California) 1 of 1
Country (United States) 6 of 9
Year (2003) 1 of 1
Size (of disclosed) 4 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2001-09-27 Novazyme Pharmaceuticals

Oklahoma City, Oklahoma, United States

Novazyme is a development stage biotechnology company focused on drugs to treat lysosomal storage diseases

Buy $137M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2004-12-21 ILEX Oncology

San Antonio, Texas, United States

ILEX Oncology, Inc. is a drug development company focused exclusively on the accelerated development of drugs for the treatment and prevention of cancer. ILEX Oncology was founded in 1992 and is based in San Antonio, Texas.

Buy $1.0B
Mergr

Product

Company

Legal